Immunomic TherapeuticsImmunomic Therapeutics
Immunomic TherapeuticsImmunomic Therapeutics
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us

Press Releases

  • Highlights
  • Events
  • Blog
  • News
  • Articles
  • Press Releases
  • Posters
  • Immunomic Therapeutics Announces Successful Completion of Series A Preferred Stock Financing Round

    Press Releases
    HERSHEY, PA & ROCKVILLE, MD (PRWEB) OCTOBER 28, 2014 Immunomic Therapeutics, Inc.(ITI), a vaccine pioneer in the biotechnology industry, today announced the successful completion of a $6.8 million Series A preferred
    Read more
12345678910
← Previous page

Content
  • Pipeline
  • Partnerships
  • Team
  • Media
  • Contact Us
Careers
  • Careers
  • Compensation & Benefits
  • Culture & Beliefs
Policies
  • Expanded Access Policy
  • Privacy Policy
Social
  • Facebook
  • X / Twitter
  • Youtube
Telephone

+1.301.968.3501

Address

15010 Broschart Road

Rockville, MD 20850

© 2020 Immunomic Therapeutics, Inc. All Rights Reserved.